Intermittent levosimendan infusions in advanced heart failure: Favourable effects on left ventricular function, neurohormonal balance, and one-year survival

Journal of Cardiovascular Pharmacology

Volumn 60, Issue 5, 2012, Pages 450-455

  Malfatto, Gabriella ^a   Della Rosa, Francesco ^a   Villani, Alessandra ^a   Rella, Valeria ^a   Branzi, Giovanna ^a   Facchini, Mario ^a   Parati, Gianfranco ^a,b  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

BNP; chronic heart failure; diastolic function; levosimendan; mitral regurgitation; thoracic bioimpedance

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; FUROSEMIDE; LEVOSIMENDAN; NEUROHORMONE;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE PERFORMANCE; HUMAN; MALE; MITRAL VALVE REGURGITATION; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; CALCIUM; CHRONIC DISEASE; DATA INTERPRETATION, STATISTICAL; DIURETICS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FUROSEMIDE; HEART FAILURE; HEART FUNCTION TESTS; HEMODYNAMICS; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; MALE; MORTALITY; NATRIURETIC PEPTIDE, BRAIN; PYRIDAZINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VENTRICULAR FUNCTION;

EID: 84870059570     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31826b86aa     Document Type: Article

References (30)

1. Metra M, Ponikowski P, Dickstein K, et al. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2007;9:684-694. (Pubitemid 46705572)
2. Dickstein K, Cohen-Solal A, Filippatos GS, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive care Medicine (ESICM). Eur Heart J 2008;29:2388-2442.
3. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759-1764. (Pubitemid 43817867)
4. Ahmed A, Young JB, Love TE, et al. A propensity-matched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure. Int J Cardiol. 2008;125:246-253. (Pubitemid 351400220)
5. Abraham WT, Adams KF, Fonarow GC, et al, and ADHERE Scientific Advisory Committee and Investigators; ADHERE Study Group. Inhospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46:57-64. (Pubitemid 40905130)
6. Sorsa T, Pollesello P, Rosevear PR, et al. Stereoselective binding of levosimendan to cardiac troponin C causes Ca2+-sensitization. Eur J Pharmacol. 2004;486:1-8. (Pubitemid 38130154)
7. Hasenfuss G, Pieske B, Castell M, et al. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 1998;98:2141-2147. (Pubitemid 28527473)
8. Yokoshiki H, Katsube Y, Sunagawa M, et al. The novel calcium sensitizer levosimendan activates the ATP-sensitive K (ATP) channel in rat ventricular cells. J Pharmacol Exp Ther. 1997;283:375-383. (Pubitemid 27438984)
9. Michaels AD, McKeown B, Kostal M, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation. 2005;111:1504-1509. (Pubitemid 40470645)
10. Kyrzopoulos S, Adamopoulos S, Parissis JT, et al. Levosimendan reduces plasma B-type natriuretic peptide and interleukin-6, and improves central hemodynamics in severe heart failure patients. Int J Cardiol. 2005;99:409-413. (Pubitemid 40363991)
11. Avgeropoulou C, Andreadou I, Markantonis-Kyroudis S, et al. The Ca (2+)-sensitizer levosimendan improves oxidative damage, BNP and proinflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail. 2005;7:882-887. (Pubitemid 41125911)
12. Moiseyev VS, Põder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, doubleblind study (RUSSLAN). Eur Heart J. 2002;23:1422-1432. (Pubitemid 36285574)
13. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196-202. (Pubitemid 34804646)
14. Mebazaa A, Nieminen MS, Filippatos GS, et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail. 2009;11:304-311.
15. Nanas JN, Papazoglou P, Tsagalou EP, et al. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am J Cardiol. 2005;95:768-771. (Pubitemid 40332658)
16. Parissis JT, Adamopoulos S, Farmakis D, et al. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart. 2006;92:1768-1772. (Pubitemid 44851320)
17. Parle NM, Thomas MD, Dembo L, et al. Repeated infusions of levosimendan: well tolerated and improve functional capacity in decompensated heart failure - a single-centre experience. Heart Lung Circ. 2008;17:206-210.
18. Branzi G, Malfatto G, Villani A, et al. Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure. J Cardiovasc Med (Hagerstown). 2010;11:662-668.
19. Gerhard-Herman M, Gardin JM, Jaff M, et al. Guidelines for noninvasive vascular laboratory testing. J Am Soc Echocardiogr. 2006;19:955-972.
20. Sohn DW, Chai IH, Lee DJ, et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol. 1997;30:474-480.
21. Bruch C, Klem I, Breithardt G, et al. Diagnostic usefulness and prognostic implications of the mitral E/E' ratio in patients with heart failure and severe secondary mitral regurgitation. Am J Cardiol. 2007;100:860-865. (Pubitemid 47268279)
22. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22:107-133.
23. Enriquez-Sarano M, Tribouilloy C. Quantitation of mitral regurgitation: rationale, approach, and interpretation in clinical practice. Heart. 2002;88:1-3.
24. Thomas JD. Doppler echocardiographic assessment of valvar regurgitation. Heart. 2002;88:651-657. (Pubitemid 35418095)
25. Malfatto G, Branzi G, Giglio A, et al. Transthoracic bioimpedance and brain natriuretic peptide levels accurately indicate additional diastolic dysfunction in patients with chronic advanced systolic heart failure. Eur J Heart Fail. 2010;12:928-935.
26. Malfatto G, Blengino S, Perego GB, et al. Transthoracic Impedance accurately estimates pulmonary wedge pressure in patients with decompensated chronic heart failure. Congest Heart Fail. 2012;18:25-31.
27. Erdei N, Papp Z, Pollesello P, et al. The levosimendan metabolite OR-1896 elicits vasodilation by activating the KATP and BKCa channels in rat isolated arterioles. Br J Pharmacol. 2006;148:696-702. (Pubitemid 43993060)
28. Lilleberg J, Laine M, Palkama T, et al. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail. 2007;9:75-82. (Pubitemid 46074480)
29. Landoni G, Biondi-Zoccai G, Greco M, et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med. 2012;40:634-646.
30. Altenberger J, Parissis JT, Ulmer H, et al, and LevoRep Investigators. Rationale and design of the multicentre randomized trial investigating the efficacy and safety of pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep study). Eur J Heart Fail. 2010;12:186-192.